ArticleImmunogenetics2008
Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy.
Article in Immunogenetics, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 1 synthesis or guideline pooled it, 130 citations in OpenAlex.
- Prognostic and Clinical Significance of Human Leukocyte Antigen Class I Expression in Breast Cancer: A Meta-Analysis.Molecular diagnosis & therapy · 2023Pooled it
- LPL-Positive Endothelial Cells Control T-cell Homing in Liver Metastasis.Cancer discovery · 2026Article
- A Phase Ib Study of Chemoimmunotherapy with Pegylated Liposomal Doxorubicin and Pembrolizumab in Estrogen Receptor-Positive Metastatic Breast Cancer.Cancer research communications · 2026Article
- Review
- Defective removal of invariant chain peptides from MHC class II suppresses tumor antigen presentation and promotes tumor growth.Cell reports · 2025Article
- Bidirectional regulation of lipid metabolism and the tumor microenvironment: new perspectives from mechanism to therapy.Frontiers in immunology · 2025Review
- Modulation of MHC expression by interferon-gamma and its influence on PBMC-mediated cytotoxicity in canine mast cell tumour cells.Scientific reports · 2024Article
- Strategies to overcome low MHC-I expression in paediatric and adult tumours.Immunotherapy advances · 2024Review
- Immune Evasion Through Human Leukocyte Antigen Implications and Its Impact on Targeted Therapy.Cureus · 2024Review
- Active Learning for Optimal Intervention Design in Causal Models.Nature machine intelligence · 2023Article
- BMI1 induces ubiquitination and protein degradation of Nod-like receptor family CARD domain containing 5 and suppresses human leukocyte antigen class I expression to induce immune escape in non-small cell lung cancer.The Kaohsiung journal of medical sciences · 2022Article
- Adoptive cell therapies in thoracic malignancies.Cancer immunology, immunotherapy : CII · 2022Review
- Tumor Antigenicity and a Pre-Existing Adaptive Immune Response in Advanced BRAF Mutant Colorectal Cancers.Cancers · 2022Article
- The Immunogenetics of Melanoma.Advances in experimental medicine and biology · 2022Article
- Article
- Antiangiogenic therapy reverses the immunosuppressive breast cancer microenvironment.Biomarker research · 2021Review
- MHC heterogeneity and response of metastases to immunotherapy.Cancer metastasis reviews · 2021Review
- HLA class I loss in colorectal cancer: implications for immune escape and immunotherapy.Cellular & molecular immunology · 2021Review
- The MHC Class-I Transactivator NLRC5: Implications to Cancer Immunology and Potential Applications to Cancer Immunotherapy.International journal of molecular sciences · 2021Review
- Lipid Metabolism and Tumor Antigen Presentation.Advances in experimental medicine and biology · 2021Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Despite the potential efficacy of cancer immunotherapy in preclinical studies, it did not show yet significant positive clinical results in humans with only a small number of cancer patients demonstrating objective tumor regression. This poor clinical outcome can be explained by the generation of sophisticated tumor immune escape mechanism, in particular, abnormalities in the expression of HLA class I antigens. We have studied the expression of HLA class I antigens in ten metastatic lesions obtained from a melanoma patient undergoing immunotherapy. Five lesions were obtained after Interferon-alpha-2b treatment and five after autologous vaccination plus BCG (M-VAX). Eight metastases were regressing after immunotherapy while two were progressing. The eight regressing metastases showed high level of HLA class I expression, whereas the two progressing lesions had low levels as measured by real time PCR and immunohistological techniques. These results indicate a strong association between HLA class I expression and progression or regression of the metastatic lesions. Our data support the hypothesis that the level of HLA class I expression is an important parameter of tumor immune escape that needs to be monitored.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.